ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,877, issued on Feb. 17, was assigned to Amgen Inc. (Thousand Oaks, Calif.).
"Anti-TL1A antibodies and uses thereof" was invented by Hailing Hsu (Moorpark, Calif.), Gunasekaran Kannan (Daly City, Calif.), Kenneth W. Walker (Newbury Park, Calif.), Michelle Hortter (Camarillo, Calif.) and Edward J. Belouski (Thousand Oaks, Calif.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-Alpha. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the...